In sufferers with resistant and refractory chronic myeloid leukemia.

ARIAD presents updated positive data on AP24534 pan-BCR-ABL inhibitor for CML in 46th ASCO ARIAD Pharmaceuticals, Inc. today announced up to date scientific data from an ongoing Phase 1 study of its investigational pan-BCR-ABL inhibitor, AP24534, in sufferers with resistant and refractory chronic myeloid leukemia . The info confirm strong clinical proof hematologic, molecular and cytogenetic anti-leukemia activity of AP24534, a multi-targeted kinase inhibitor, in heavily pretreated patients with CML, including those with the T315I mutation of the mark protein, BCR-ABL rx pills .

Cohort to begin with in May 2015. To find out more or to register, please visit About the American Pharmacists Association The American Pharmacists Association, founded in 1852 as the American Pharmaceutical Association, is certainly a 501 organization, representing a lot more than 62,000 practicing pharmacists, pharmaceutical researchers, student pharmacists, pharmacy professionals and others interested in advancing the profession. APhA, dedicated to assisting all pharmacists improve medicine advance and use patient care, is the largest and first-established association of pharmacists in the usa. To find out more, please visit.. PRESS RELEASE WASHINGTON, DC – The American Pharmacists Association released its newest education training curriculum, ADAPT, from the 2015 APhA Annual Exposition and Getting together with, APhA2015.